Medivir

Medivir kick-started 2024 in January by presenting positive results from the phase 1b/2a study in advanced liver cancer (HCC) with the fostrox + Lenvima combination at the ASCO GI Congress. The good results, which showed promising response and time to progression, attracted quite some attention, and were then gradually improved during the year. The final results were presented in February 2025 and showed data that is significantly better than what was previously shown in second-line liver cancer.
 
In parallel with the phase 1b/2a study, Medivir has worked on preparations for the next major and crucial step - the planned phase 2b study in second-line advanced liver cancer. The combination fostrox + Lenvima may become the first approved second-line treatment for these vulnerable patients.
 
The 2024 annual report describes the study, its results and implications in more detail. It also provides a picture of the preparations for the planned pivotal study, the study design, the interactions with the regulatory authorities, the collaboration with Esai, and Medivir's work to ensure that fostrox meets all the requirements for a market-approved drug. The other projects in Medivir's pipeline are also described here, both those where development is driven by partners and those intended to be licensed out to partners, and how these have developed during the year.
 
This and much more can be found in Medivir's Annual Report 2024, published today at the website;
https://www.medivir.com/investors/reports#FinancialReports2024